Canadian Scientist Awarded Breakthrough Prize for Pioneering Hormone Discovery Behind Ozempic and Mounjaro
A leading Canadian scientist has received the prestigious Breakthrough Prize in Life Sciences for a groundbreaking discovery that paved the way for two of the most talked-about drugs in modern medicine—Ozempic and Mounjaro. These medications, which have revolutionized the treatment of type 2 diabetes and obesity, are based on the hormone uncovered during the scientist’s pivotal research.
Dr. Daniel Drucker, a professor of medicine at the University of Toronto and a senior researcher at the Lunenfeld-Tanenbaum Research Institute, was recognized for his discovery of GLP-1 (glucagon-like peptide-1), a gut hormone that regulates insulin secretion and blood sugar levels. This finding laid the scientific foundation for the development of GLP-1 receptor agonist drugs, including the widely used Ozempic and the newer, dual-action drug Mounjaro.
The Breakthrough Prize, often referred to as the “Oscars of Science,” awards $3 million to scientists whose work has profoundly advanced human knowledge. Dr. Drucker’s research not only contributed to a significant scientific breakthrough but also helped improve the lives of millions living with diabetes and obesity across the globe.
GLP-1 mimicking drugs have grown in popularity not only for their role in managing blood sugar levels but also for their substantial impact on weight loss—a major secondary benefit that has led to increasing demand worldwide. Both Ozempic (semaglutide) and Mounjaro (tirzepatide) have been hailed as transformative medications, offering a new line of defense against two of the most pervasive health issues of the 21st century.
In accepting the award, Dr. Drucker emphasized the decades of research that led to this success. “This recognition underscores the value of basic science and the importance of persistence in medical research,” he said. “What began as curiosity-driven work in a laboratory has now translated into real-world therapies that are changing lives.”
Experts in the medical and pharmaceutical communities have praised Dr. Drucker’s work, noting that it bridges the gap between molecular biology and practical treatment. His contributions also highlight the crucial role Canadian institutions play in global healthcare innovation.
As interest in GLP-1-based medications continues to surge—especially with their increasing use in weight management—Dr. Drucker’s foundational research is receiving renewed attention. With global pharmaceutical companies investing heavily in further developments, including oral versions and combination therapies, the impact of his discovery is poised to grow even more in the coming years.
The award serves not only as a personal milestone for Dr. Drucker but also as a testament to the enduring power of scientific inquiry in shaping the future of medicine.
Source : The Canadian Press
